US FDA Throws Acadia A Curveball On Nuplazid For Dementia Psychosis
Complete Response Letter Requires More Data
Executive Summary
Acadia strikes out on potential near-term sNDA approval in a broad dementia-related psychosis indication. The firm said the agency’s view has shifted from what was previously agreed upon.
You may also be interested in...
Acadia's Nuplazid Expansion Bid Bites The Dust
Nuplazid is a decent earner for the US biotech in psychosis caused by Parkinson’s disease but following previous failures in Alzheimer's and dementia, the drug has now proved a dud for treating the negative symptoms of schizophrenia.
Keeping Track: Enhertu, Nubeqa Grow With RTOR; Interchangeable Cimerli And Another Nuplazid CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Future Of Acadia’s Nuplazid In Alzheimer’s Psychosis Unclear After CRL
An analyst had suggested that in the event of a thumbs-down from the FDA, the company could end up focusing on other catalysts instead.